Dome Therapeutics

Dome Therapeutics is a biotechnology company focused on developing novel therapies for inflammatory skin diseases by leveraging the biology of skin-resident regulatory T cells (Tregs). Founded by Dr. Michael Rosenblum of UCSF, the company's approach centers on restoring immune balance in the skin to treat conditions like atopic dermatitis and psoriasis. In early 2020, the company was acquired by Eli Lilly to bolster its immunology pipeline. The acquisition integrated Dome's Treg-modulating programs into Lilly's broader dermatology and inflammation portfolio. The company operated primarily in stealth mode prior to its acquisition, focusing on the translation of academic research into clinical candidates.